semaglutide 7.2 mg clinical trial The FDA has approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, Wegovy HD, for weight loss and long-term weight maintenance in certain adult patients—in just 54 days from filing Wegovy HD 7.2mg Now Available

New Jersey has organized a multicounty litigation to coordinate Ozempic and Wegovy vision loss claims, while additional individual cases are being filed in other states

When someone says they inject 20 units of semaglutide, they are injecting 0.2mL of whatever concentration their vial contains

Weight loss can also lead to improved physical activity, an important lifestyle habit that can further improve cardiovascular health

After your first injection, log the following on a simple spreadsheet or notes app: Time of injection

The most common side effects from taking Semaglutide and Tirzepatide include, but are not limited to: Nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, hypotension, abdominal distension (bloating), eructation (burping), hypoglycemia in patients with type 2 diabetes, flatulence (gas), gastroenteritis, gastroesophageal reflux disease, injection site reactions, allergic reactions, and hair loss